What is the main reason for the significant revenue decline?

The primary driver for the revenue decline is the loss of exclusivity for key products, most notably Lipitor. This has led to increased generic competition and a substantial decrease in sales for these products.

How did Pfizer manage to increase its income from continuing operations despite lower revenues?

The increase in income from continuing operations was largely due to a favorable tax settlement with the IRS, which resulted in a significant tax benefit. Additionally, Pfizer benefited from lower restructuring charges, acquisition-related costs, and R&D expenses compared to the prior year's period.

What are Pfizer's strategic plans for its non-core businesses?

Pfizer is actively divesting its non-core assets. The company has an agreement to sell its Nutrition business to Nestlé and is planning an initial public offering (IPO) for its Animal Health business, Zoetis, with the potential for a full separation.

What is the outlook for Pfizer's R&D spending and product pipeline?

Pfizer is focusing its R&D efforts on five high-priority therapeutic areas. While R&D expenses have decreased due to cost-saving initiatives, the company continues to invest in its pipeline through internal development and external collaborations, aiming to bring new differentiated products to market.

PFE 10-Q Filed Nov 9, 2012

Summary

Pfizer Inc.'s third-quarter 2012 filing reflects a period of significant revenue decline, primarily driven by the loss of exclusivity for its blockbuster drug Lipitor. Revenues for the quarter fell by 16% year-over-year to $14.0 billion, with an operational decline of 12%. This downturn was exacerbated by unfavorable foreign exchange rates. Despite the revenue challenges, Pfizer reported an increase in income from continuing operations to $3.1 billion, up from $2.3 billion in the prior year's quarter. This improvement was largely due to a substantial tax benefit of approximately $1.1 billion resulting from a settlement with the IRS, as well as reduced restructuring and acquisition-related costs compared to the previous year. The company is actively managing its portfolio, with plans to divest its Nutrition business to Nestlé and potentially spin off its Animal Health division. These strategic moves aim to streamline operations and focus on core biopharmaceutical strengths. Pfizer also continues to invest in research and development, focusing on five high-priority therapeutic areas, while also facing ongoing legal proceedings and patent litigation, which are detailed in the filing.

Key Highlights

1Revenues decreased by 16% to $14.0 billion in Q3 2012 compared to Q3 2011, primarily due to the loss of exclusivity for Lipitor.
2Income from continuing operations increased by 34% to $3.1 billion in Q3 2012, driven by a significant tax benefit from an IRS settlement and lower expenses.
3The company is in the process of selling its Nutrition business to Nestlé for $11.85 billion, expected to close in the near future.
4Pfizer filed for a potential IPO of up to 20% of its Animal Health business, Zoetis, targeting the first half of 2013.
5Research and Development (R&D) expenses decreased by 9% in Q3 2012, reflecting cost-saving initiatives.
6The company made progress in resolving various legal and tax matters, including a significant settlement with the IRS that provided a substantial tax benefit.
7Despite revenue declines from key products like Lipitor, the company saw growth in other products such as Lyrica and Celebrex.

PFIZER INC Quarterly Report for Q3 Ended Sep 30, 2012

Summary

Key Highlights

Frequently Asked Questions